Cargando…
Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies
Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced translocations (N = 27) and telomeric rearrangements (N = 15), both mai...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198844/ https://www.ncbi.nlm.nih.gov/pubmed/22039459 http://dx.doi.org/10.1371/journal.pone.0026311 |
_version_ | 1782214497857961984 |
---|---|
author | Duhoux, Francois P. Ameye, Geneviève Lambot, Virginie Herens, Christian Lambert, Frédéric Raynaud, Sophie Wlodarska, Iwona Michaux, Lucienne Roche-Lestienne, Catherine Labis, Elise Taviaux, Sylvie Chapiro, Elise Khac, Florence Nguyen Struski, Stéphanie Dobbelstein, Sophie Dastugue, Nicole Lippert, Eric Speleman, Frank Van Roy, Nadine De Weer, An Rack, Katrina Talmant, Pascaline Richebourg, Steven Mugneret, Francine Tigaud, Isabelle Mozziconacci, Marie-Joëlle Laibe, Sophy Nadal, Nathalie Terré, Christine Libouton, Jeanne-Marie Decottignies, Anabelle Vikkula, Miikka Poirel, Hélène A. |
author_facet | Duhoux, Francois P. Ameye, Geneviève Lambot, Virginie Herens, Christian Lambert, Frédéric Raynaud, Sophie Wlodarska, Iwona Michaux, Lucienne Roche-Lestienne, Catherine Labis, Elise Taviaux, Sylvie Chapiro, Elise Khac, Florence Nguyen Struski, Stéphanie Dobbelstein, Sophie Dastugue, Nicole Lippert, Eric Speleman, Frank Van Roy, Nadine De Weer, An Rack, Katrina Talmant, Pascaline Richebourg, Steven Mugneret, Francine Tigaud, Isabelle Mozziconacci, Marie-Joëlle Laibe, Sophy Nadal, Nathalie Terré, Christine Libouton, Jeanne-Marie Decottignies, Anabelle Vikkula, Miikka Poirel, Hélène A. |
author_sort | Duhoux, Francois P. |
collection | PubMed |
description | Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced translocations (N = 27) and telomeric rearrangements (N = 15), both mainly observed in myeloid disorders; and unbalanced non-telomeric rearrangements (N = 39), mainly observed in lymphoid proliferations and frequently associated with a highly complex karyotype. The 1p36 rearrangement was isolated in 12 cases, mainly myeloid disorders. The breakpoints on 1p36 were more widely distributed than previously reported, but with identifiable rare breakpoint cluster regions, such as the TP73 locus. We also found novel partner loci on 1p36 for the known multi-partner genes HMGA2 and RUNX1. We precised the common terminal 1p36 deletion, which has been suggested to have an adverse prognosis, in B-cell lymphomas [follicular lymphomas and diffuse large B-cell lymphomas with t(14;18)(q32;q21) as well as follicular lymphomas without t(14;18)]. Intrachromosomal telomeric repetitive sequences were detected in at least half the cases of telomeric rearrangements. It is unclear how the latter rearrangements occurred and whether they represent oncogenic events or result from chromosomal instability during oncogenesis. |
format | Online Article Text |
id | pubmed-3198844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31988442011-10-28 Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies Duhoux, Francois P. Ameye, Geneviève Lambot, Virginie Herens, Christian Lambert, Frédéric Raynaud, Sophie Wlodarska, Iwona Michaux, Lucienne Roche-Lestienne, Catherine Labis, Elise Taviaux, Sylvie Chapiro, Elise Khac, Florence Nguyen Struski, Stéphanie Dobbelstein, Sophie Dastugue, Nicole Lippert, Eric Speleman, Frank Van Roy, Nadine De Weer, An Rack, Katrina Talmant, Pascaline Richebourg, Steven Mugneret, Francine Tigaud, Isabelle Mozziconacci, Marie-Joëlle Laibe, Sophy Nadal, Nathalie Terré, Christine Libouton, Jeanne-Marie Decottignies, Anabelle Vikkula, Miikka Poirel, Hélène A. PLoS One Research Article Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced translocations (N = 27) and telomeric rearrangements (N = 15), both mainly observed in myeloid disorders; and unbalanced non-telomeric rearrangements (N = 39), mainly observed in lymphoid proliferations and frequently associated with a highly complex karyotype. The 1p36 rearrangement was isolated in 12 cases, mainly myeloid disorders. The breakpoints on 1p36 were more widely distributed than previously reported, but with identifiable rare breakpoint cluster regions, such as the TP73 locus. We also found novel partner loci on 1p36 for the known multi-partner genes HMGA2 and RUNX1. We precised the common terminal 1p36 deletion, which has been suggested to have an adverse prognosis, in B-cell lymphomas [follicular lymphomas and diffuse large B-cell lymphomas with t(14;18)(q32;q21) as well as follicular lymphomas without t(14;18)]. Intrachromosomal telomeric repetitive sequences were detected in at least half the cases of telomeric rearrangements. It is unclear how the latter rearrangements occurred and whether they represent oncogenic events or result from chromosomal instability during oncogenesis. Public Library of Science 2011-10-21 /pmc/articles/PMC3198844/ /pubmed/22039459 http://dx.doi.org/10.1371/journal.pone.0026311 Text en Duhoux et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Duhoux, Francois P. Ameye, Geneviève Lambot, Virginie Herens, Christian Lambert, Frédéric Raynaud, Sophie Wlodarska, Iwona Michaux, Lucienne Roche-Lestienne, Catherine Labis, Elise Taviaux, Sylvie Chapiro, Elise Khac, Florence Nguyen Struski, Stéphanie Dobbelstein, Sophie Dastugue, Nicole Lippert, Eric Speleman, Frank Van Roy, Nadine De Weer, An Rack, Katrina Talmant, Pascaline Richebourg, Steven Mugneret, Francine Tigaud, Isabelle Mozziconacci, Marie-Joëlle Laibe, Sophy Nadal, Nathalie Terré, Christine Libouton, Jeanne-Marie Decottignies, Anabelle Vikkula, Miikka Poirel, Hélène A. Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies |
title | Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies |
title_full | Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies |
title_fullStr | Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies |
title_full_unstemmed | Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies |
title_short | Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies |
title_sort | refinement of 1p36 alterations not involving prdm16 in myeloid and lymphoid malignancies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198844/ https://www.ncbi.nlm.nih.gov/pubmed/22039459 http://dx.doi.org/10.1371/journal.pone.0026311 |
work_keys_str_mv | AT duhouxfrancoisp refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT ameyegenevieve refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT lambotvirginie refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT herenschristian refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT lambertfrederic refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT raynaudsophie refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT wlodarskaiwona refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT michauxlucienne refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT rochelestiennecatherine refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT labiselise refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT taviauxsylvie refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT chapiroelise refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT khacflorencenguyen refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT struskistephanie refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT dobbelsteinsophie refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT dastuguenicole refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT lipperteric refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT spelemanfrank refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT vanroynadine refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT deweeran refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT rackkatrina refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT talmantpascaline refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT richebourgsteven refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT mugneretfrancine refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT tigaudisabelle refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT mozziconaccimariejoelle refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT laibesophy refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT nadalnathalie refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT terrechristine refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT liboutonjeannemarie refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT decottigniesanabelle refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT vikkulamiikka refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT poirelhelenea refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies AT refinementof1p36alterationsnotinvolvingprdm16inmyeloidandlymphoidmalignancies |